Oragenics Inc OGEN

Healthcare Biotechnology

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.

NYSEAM:OGEN - Post by User

Oragenics Inc

<< Previous

Bullboard Posts

Post by whytestockson Sep 04, 2024 5:17pm

157 Views

Post# 36208800

BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Ente

Breaking News: $OGEN BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M2024-09-04 14:21:26 ET Oragenics (NYSE American: OGEN) , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has entered into a placement agency agreement. The agreement is for the purchase and sale of 8,106,584 shares...OGEN - BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M

<< Previous

Bullboard Posts

Anaergia signs $25M biomethane deal in Italy